| P50 | author | Aditya K. Gupta | Q40037766 |
| P2093 | author name string | N H Shear | |
| P2860 | cites work | Meta-analysis in clinical trials | Q27860779 |
| | Terbinafine: mode of action and properties of the squalene epoxidase inhibition | Q28284524 |
| | Treatment of Candida nail infection with terbinafine | Q28299342 |
| | Antifungal activity of the allylamine derivative terbinafine in vitro | Q28361964 |
| | Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil). | Q31047502 |
| | Clinical and economic factors in the treatment of onychomycosis | Q33571891 |
| | Terbinafine in onychomycosis with involvement by non-dermatophytic fungi | Q34341344 |
| | Black piedra: the first case treated with terbinafine (Lamisil). | Q34341348 |
| | Clinical singgnificance of interactions with antifungal agents | Q35225764 |
| | Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses | Q35312015 |
| | A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole | Q36750424 |
| | Onychomycosis in children: prevalence and treatment strategies | Q36852556 |
| | Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group | Q36905131 |
| | Management of drug therapy in the elderly | Q38662035 |
| | Clinical pharmacokinetics of terbinafine (Lamisil). | Q38738795 |
| | Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study | Q38995710 |
| | Hepatitis associated with terbinafine treatment | Q40349541 |
| | Overview of the use of terbinafine (Lamisil) in children. | Q40540201 |
| | Meta-analysis for combining Bayesian probabilities | Q41170547 |
| | Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis | Q41467169 |
| | Treatment of cutaneous sporotrichosis with terbinafine. | Q41863966 |
| | Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers | Q41916916 |
| | Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics | Q42684596 |
| | Human Trichophyton equinum infection treated with terbinafine | Q43212914 |
| | Terbinafine-associated hepatic injury | Q44033076 |
| | Open randomized comparison of itraconazole versus terbinafine in onychomycosis | Q44284595 |
| | A randomized treatment duration-finding study of terbinafine in onychomycosis | Q44394183 |
| | Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy | Q44634619 |
| | Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model | Q44704443 |
| | Terbinafine in onychomycosis of the toenail: A novel treatment protocol | Q44773162 |
| | Treatment of onychomycosis with terbinafine | Q46333836 |
| | The interaction of representative members from two classes of antimycotics--the azoles and the allylamines--with cytochromes P-450 in steroidogenic tissues and liver | Q46631239 |
| | One-week therapy with oral terbinafine in cases of tinea cruris/corporis | Q46731129 |
| | The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine | Q48926074 |
| | Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. | Q52874065 |
| | Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. | Q52876198 |
| | Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. | Q53986887 |
| | An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis | Q54067663 |
| | Hypersensitivity reaction to terbinafine | Q58404949 |
| | Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. | Q64931892 |
| | Azoles, a48 llylamines and drug metabolism | Q67486478 |
| | Single dose treatment of fungal nail disease | Q67515804 |
| | Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum | Q67999975 |
| | Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers | Q68068784 |
| | A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris | Q68523004 |
| | Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis | Q68586325 |
| | A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections | Q70123965 |
| | Terbinafine and fixed drug eruption | Q70883208 |
| | Nail incorporation kinetics of terbinafine in onychomycosis patients | Q70983419 |
| | Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans | Q71196404 |
| | Onychomycosis treated with a short course of oral terbinafine | Q71333728 |
| | Toxic epidermal necrolysis induced by terbinafine in a patient on long-term anti-epileptics | Q71361343 |
| | A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day--a double-blind comparative trial | Q71415816 |
| | A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis | Q71453022 |
| | Very short duration therapy with oral terbinafine for fingernail onychomycosis | Q71714037 |
| | Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach | Q71815829 |
| | Terbinafine in the treatment of Majocchi's granuloma | Q71820427 |
| | Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany | Q71835802 |
| | Efficacy of terbinafine treatment of tinea capitis in children varies according to the dermatophyte species | Q71931745 |
| | Treatment of onychomycosis with terbinafine in patients with Down's syndrome | Q72046269 |
| | Oral terbinafine and erythema multiforme | Q72050482 |
| | Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days | Q72106098 |
| | Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis | Q72168291 |
| | Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole | Q72227161 |
| | Stevens-Johnson syndrome after terbinafine therapy | Q72255223 |
| | Treatment of childhood dermatophyte infections with oral terbinafine | Q72337797 |
| | Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group | Q72411794 |
| | Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study | Q72426580 |
| | Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective | Q72426588 |
| | A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group | Q72426592 |
| | Terbinafine and erythema multiforme | Q72772230 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | terbinafine | Q415259 |
| P304 | page(s) | 979-988 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | Terbinafine: an update | |
| P478 | volume | 37 | |